SurModics Inc (SRDX)

[Democritus_of_Abdera]

Fab fragment release from SRDX polymers.

There are at least 5 presentations at the upcoming ARVO meeting which describe release kinetics and safety of SRDX polymers.

See: http://www.abstractsonline.com/viewer/?mkey=%7B0AEC998A%2D0BCA%2D41AF%2DA530%2D43715608C824%7D

Two of the abstracts describe release kinetics of anti-goat Fab fragments from biodegradable polysaccharide devices. One of the divices was a rod intravitreal implant, 5 mm in length and 0.5 mm in diameter, with a biodegradable coating formulated from low molecular weight polysaccharides. The other was an I-vation intravitreal implant coated with a blend of biodegradable polyethylene glycol polymers. Good in vivo release kinetics is described for the first 4 weeks after implantation.

The other three abstracts reference Triamcinolone release. One of the abstracts reports that the I-vation TA intravitreal implants are well tolerated and associated with improvements in macular thickness. Another describes controlled release of Triamcinolone for up to a year from a biodegradable polymer. The third evaluates the safety of a subretinal implant containing Triamcinolone.

Surmodics has reserved a booth in the exhibit hall.

The ARVO meetings will be held May 6-10, 2007 in Fort Lauderdale, Florida. The Association for Research in Vision and Ophthalmology and is a major meeting for both academic and clinical professionals.